EHF
MCID: EBL001
MIFTS: 55

Ebola Hemorrhagic Fever (EHF)

Categories: Infectious diseases, Mental diseases, Muscle diseases, Oral diseases, Rare diseases

Aliases & Classifications for Ebola Hemorrhagic Fever

MalaCards integrated aliases for Ebola Hemorrhagic Fever:

Name: Ebola Hemorrhagic Fever 12 58 29 15 17
Ebola Virus Disease 12 73 20 58 3 32
Hemorrhagic Fever, Ebola 44 70
Ebola Fever 58
Ehf 58

Characteristics:

Orphanet epidemiological data:

58
ebola hemorrhagic fever
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Ebola Hemorrhagic Fever

Disease Ontology : 12 A viral infectious disease that is a hemorrhagic fever, has material basis in Zaire ebolavirus, has material basis in Sudan ebolavirus, has material basis in Cote d'Ivoire ebolavirus, or has material basis in Bundibugyo ebolavirus, which are transmitted by contact with the body fluids of an infected animal or person, transmitted by contaminated fomites, or transmitted by infected medical equipment. The infection has symptom fever, has symptom headache, has symptom joint pain, has symptom muscle aches, has symptom sore throat, has symptom weakness, has symptom diarrhea, has symptom vomiting, has symptom stomach pain, has symptom rash, has symptom red eyes, has symptom hiccups, and has symptom internal and external bleeding.

MalaCards based summary : Ebola Hemorrhagic Fever, also known as ebola virus disease, is related to variola major and exanthem, and has symptoms including vomiting, fever and headache. An important gene associated with Ebola Hemorrhagic Fever is GTPBP1 (GTP Binding Protein 1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Cytokine Signaling in Immune system. The drugs Coal tar and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include eye, lung and skin, and related phenotypes are fatigue and recurrent pharyngitis

CDC : 3 Ebola Virus Disease (EVD) is a rare and deadly disease in people and nonhuman primates. The viruses that cause EVD are located mainly in sub-Saharan Africa. People can get EVD through direct contact with an infected animal (bat or nonhuman primate) or a sick or dead person infected with Ebola virus. There is no approved vaccine or treatment for EVD. Research on EVD focuses on finding the virus' natural host, developing vaccines to protect at-risk populations, and discovering therapies to improve treatment of the disease.

Wikipedia : 73 Ebola, also known as Ebola virus disease (EVD) or Ebola hemorrhagic fever (EHF), is a viral hemorrhagic... more...

Related Diseases for Ebola Hemorrhagic Fever

Diseases related to Ebola Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 320)
# Related Disease Score Top Affiliating Genes
1 variola major 30.5 CD8A CD4
2 exanthem 30.4 IFNA1 F3 CD8A CD4
3 covid-19 30.3 IFNB1 IFNA1 F3 CXCL10
4 meningoencephalitis 30.3 CXCL10 CD8A CD4
5 middle east respiratory syndrome 30.2 IRF3 IFNB1 FURIN CXCL10
6 respiratory failure 30.2 F3 CXCL10 CD8A CD4
7 venezuelan equine encephalitis 30.2 IFNB1 IFNA1 CXCL10
8 disease by infectious agent 30.2 IFNB1 IFNA1 CD8A CD4 CCL4
9 gastroduodenitis 30.2 CD8A CD4
10 plague 30.1 DDX58 CD8A CD4
11 poliomyelitis 30.1 IFNA1 DDX58 CD8A CD4
12 dengue disease 30.1 IFNB1 IFNA1 ERVW-1 CD8A CCL4
13 vaccinia 29.8 IRF3 IFNB1 IFNA1 ERVW-1 CCL4
14 dermatitis, atopic 29.8 CXCL10 CD8A CD4 CCL4
15 parainfluenza virus type 3 29.8 IFNB1 IFNA1 DDX58
16 marburg hemorrhagic fever 29.8 NPC1 IFNA1 GTPBP1 GP2 FURIN F3
17 malaria 29.8 IFNB1 IFNA1 F3 CXCL10 CD8A CD4
18 yellow fever 29.7 IFNB1 DDX58 CXCL10
19 rabies 29.6 IRF3 IFNA1 DDX58 CXCL10
20 stomatitis 29.6 IFNB1 IFNA1 DDX58 CD4
21 mycobacterium tuberculosis 1 29.6 IFNB1 CXCL10 CD8A CD4 CCL4
22 argentine hemorrhagic fever 29.6 IFNA1 GTPBP1 GP2 ERVW-1 DDX58
23 measles 29.4 IRF3 IFNB1 IFNA1 DDX58
24 lassa fever 29.3 NPC1 IRF3 IFNA1 GTPBP1 GP2 ERVW-1
25 skin disease 29.2 IFNA1 DDX58 CXCL10 CD8A CD4
26 severe acute respiratory syndrome 29.1 IRF3 IFNB1 IFNA1 FURIN DDX58 CXCL10
27 crimean-congo hemorrhagic fever 29.0 IFNB1 IFNA1 FURIN F3 DDX58 CXCL10
28 encephalitis 28.9 IRF3 IFNB1 ERVW-1 DDX58 CXCL10 CCL4
29 disease of mental health 28.7 NPC1 IFNB1 IFNA1 FURIN F3 ERVW-1
30 hemorrhagic disease 28.5 IRF3 IFNB1 IFNA1 GTPBP1 GP2 F5
31 immune deficiency disease 28.3 IRF3 IFNB1 IFNA1 FURIN ERVW-1 CXCL10
32 cow milk allergy 10.9
33 allergic urticaria 10.9
34 infiltrative basal cell carcinoma 10.9
35 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.6
36 uveitis 10.5
37 blessig's cysts 10.4 GTPBP1 GP2
38 viral hemorrhagic fever 10.4
39 de quervain disease 10.4 GTPBP1 GP2
40 brazilian hemorrhagic fever 10.4 GTPBP1 GP2
41 venezuelan hemorrhagic fever 10.4 GTPBP1 GP2
42 acquired hemophilia 10.4 F5 F3
43 acquired hemophilia a 10.4 F5 F3
44 catastrophic antiphospholipid syndrome 10.4 F5 F3
45 st. louis encephalitis 10.4 IFNA1 ERVW-1
46 cerebral sinovenous thrombosis 10.4 F5 F3
47 yemenite deaf-blind hypopigmentation syndrome 10.3
48 disseminated intravascular coagulation 10.3
49 cork-handlers' disease 10.3 CD8A CD4
50 oral erosive lichen 10.3 IFNB1 IFNA1

Graphical network of the top 20 diseases related to Ebola Hemorrhagic Fever:



Diseases related to Ebola Hemorrhagic Fever

Symptoms & Phenotypes for Ebola Hemorrhagic Fever

Human phenotypes related to Ebola Hemorrhagic Fever:

58 31 (show all 28)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
2 recurrent pharyngitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100776
3 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
4 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
5 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
6 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
7 gastrointestinal hemorrhage 58 31 frequent (33%) Frequent (79-30%) HP:0002239
8 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
9 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
10 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
11 leukopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001882
12 restrictive ventilatory defect 58 31 frequent (33%) Frequent (79-30%) HP:0002091
13 cardiac arrest 58 31 frequent (33%) Frequent (79-30%) HP:0001695
14 chemosis 58 31 frequent (33%) Frequent (79-30%) HP:0012375
15 proteinuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0000093
16 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
17 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
18 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
19 macule 58 31 occasional (7.5%) Occasional (29-5%) HP:0012733
20 skin rash 58 31 occasional (7.5%) Occasional (29-5%) HP:0000988
21 gingival bleeding 58 31 occasional (7.5%) Occasional (29-5%) HP:0000225
22 lethargy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001254
23 coma 58 31 occasional (7.5%) Occasional (29-5%) HP:0001259
24 acute hepatic failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0006554
25 metrorrhagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100608
26 seizure 31 occasional (7.5%) HP:0001250
27 seizures 58 Occasional (29-5%)
28 abnormal bleeding 58 Occasional (29-5%)

Symptoms:

12 (show all 13)
  • vomiting
  • fever
  • headache
  • diarrhea
  • sore throat
  • weakness
  • stomach pain
  • rash
  • joint pain
  • muscle aches
  • red eyes
  • hiccups
  • internal

UMLS symptoms related to Ebola Hemorrhagic Fever:


fever; pruritus

GenomeRNAi Phenotypes related to Ebola Hemorrhagic Fever according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.28 F5 KPNA5
2 Decreased viability GR00342-S-2 9.28 CD4
3 Decreased viability GR00381-A-1 9.28 HDX
4 Decreased viability GR00386-A-1 9.28 HDX IFNB1
5 Decreased viability GR00402-S-2 9.28 CD8A GP2 HDX

MGI Mouse Phenotypes related to Ebola Hemorrhagic Fever:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.28 CD4 CD8A F3 FURIN GP2 GTPBP1

Drugs & Therapeutics for Ebola Hemorrhagic Fever

Drugs for Ebola Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Coal tar Approved Phase 2, Phase 3 8007-45-2
2 Vaccines Phase 3
3 polysaccharide-K Phase 3
4 Iron-Dextran Complex Phase 3
5
Irbesartan Approved, Investigational Phase 1, Phase 2 138402-11-6 3749
6
Angiotensin II Approved, Investigational Phase 1, Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198
7
Azithromycin Approved Phase 1, Phase 2 83905-01-5 55185 447043
8
Atorvastatin Approved Phase 1, Phase 2 134523-00-5 60823
9
Sunitinib Approved, Investigational Phase 1, Phase 2 341031-54-7, 557795-19-4 5329102
10
Lumefantrine Approved Phase 2 82186-77-4 6437380
11
Artemether Approved Phase 2 71963-77-4 119380 9796294 68911
12 Antimetabolites Phase 1, Phase 2
13 Anticholesteremic Agents Phase 1, Phase 2
14 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1, Phase 2
15 Angiogenesis Inhibitors Phase 1, Phase 2
16
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
17 Hypolipidemic Agents Phase 1, Phase 2
18 Giapreza Phase 1, Phase 2
19 Angiotensin Receptor Antagonists Phase 1, Phase 2
20 Angiotensinogen Phase 1, Phase 2
21 Angiotensin II Type 1 Receptor Blockers Phase 1, Phase 2
22 Protein Kinase Inhibitors Phase 1, Phase 2
23 Lipid Regulating Agents Phase 1, Phase 2
24 Antihypertensive Agents Phase 1, Phase 2
25 Antidiarrheals Phase 2
26 Vitamins Phase 2
27 Artemether, Lumefantrine Drug Combination Phase 2
28 Immunoglobulins Phase 2
29 Antibodies Phase 2
30 Antibodies, Monoclonal Phase 2
31 Immunologic Factors Phase 2
32
Edetic Acid Approved, Vet_approved Phase 1 60-00-4, 62-33-9 6049
33
Pentetic acid Approved Phase 1 67-43-6
34
carbamide peroxide Approved Phase 1 124-43-6
35
Thrombin Approved, Investigational Phase 1
36
Creatine Approved, Investigational, Nutraceutical Phase 1 57-00-1 586
37
Aspartic acid Approved, Nutraceutical Phase 1 56-84-8 5960
38 Hemagglutinins Phase 1
39 Immunoglobulin M Phase 1
40 Immunoglobulins, Intravenous Phase 1
41 Immunoglobulin G Phase 1
42 Anti-Inflammatory Agents, Non-Steroidal Phase 1
43 Anti-Inflammatory Agents Phase 1
44 N-Methylaspartate Phase 1
45 Thromboplastin Phase 1
46
L-Alanine Nutraceutical Phase 1 56-41-7 5950
47 Antibiotics, Antitubercular

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 01 - GamEvac-Combi-2016 " International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi - Combined Vector-Based Vaccine Against Ebola Virus Disease, 0.5 ml+0.5 ml/Dose " Completed NCT03072030 Phase 4
2 A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola Completed NCT02509494 Phase 3
3 An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP Completed NCT03161366 Phase 3
4 A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients With Ebola Virus Disease Completed NCT03719586 Phase 2, Phase 3 ZMapp;Remdesivir;MAb114;REGN-EB3
5 [rVSVΔG-ZEBOV] Ebola Prevention Vaccine Evaluation in Sierra Leone Completed NCT02378753 Phase 2, Phase 3
6 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Completed NCT02342171 Phase 2, Phase 3
7 A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a High Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults Completed NCT02503202 Phase 3
8 Evaluation of a Heterologous, Two-dose Preventive Ebola Vaccine for Effectiveness and Safety in the Democratic Republic of the Congo Active, not recruiting NCT04152486 Phase 3
9 A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Active, not recruiting NCT02661464 Phase 3
10 Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Withdrawn NCT02307591 Phase 2, Phase 3 Best Supportive Care;Best Supportive Care + Amiodarone
11 An Adaptive Randomized Trial Comparing Multiple Treatments for Ebola Virus (EBOV) Infected Children and Adults Unknown status NCT02380625 Phase 1, Phase 2 Azithromycin;Sunitinib and Erlotinib;Atorvastatin and Irbesartan
12 A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine Candidate in HIV-Infected Adults and Adolescents Unknown status NCT03031912 Phase 2
13 Efficacy of Favipiravir Against Severe Ebola Virus Disease Completed NCT02662855 Phase 2 Favipiravir
14 Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea Completed NCT02329054 Phase 2 Favipiravir
15 A Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV and MVA-BN®-Filo in Infants Aged 4-11 Months in Guinea and Sierra Leone Completed NCT03929757 Phase 2
16 A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults in Sierra Leone Completed NCT02575456 Phase 2
17 PREVAIL VII: Persistence of Ebola Virus in Aqueous Humor and Outcomes of Cataract Surgery in Survivors of Ebola Virus Disease Completed NCT03309020 Phase 1, Phase 2
18 A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa Completed NCT02564523 Phase 2
19 A Randomized, Observer-blind, Placebo-controlled, Two-part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo Completed NCT02598388 Phase 2
20 PREVAIL IV: Double-Blind, Randomized, Two-Phase, Placebo-Controlled, Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen Completed NCT02818582 Phase 2 GS-5734
21 A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults in Europe Completed NCT02416453 Phase 2
22 A Phase I/II Double-blind, Randomized, Placebo Controlled, Safety and Immunogenicity, Dose-finding Trial of the Monovalent Zaire Ebola Chimpanzee Adenovirus Vector Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland Completed NCT02289027 Phase 1, Phase 2
23 A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection Completed NCT02363322 Phase 1, Phase 2 B/Current Standard of Care Plus ZMapp
24 A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of Medicinal Product GamEvac-Lyo, Vector-Based Vaccine Against Ebola Virus Disease, Lyophilisate for Preparation of Solution for Intramuscular Injection Completed NCT03333538 Phase 1, Phase 2
25 An Open-label, Single Arm Study to Provide Additional Information on Immunogenicity and Safety of Ad26.ZEBOV/MVA-BN-Filo Recruiting NCT04028349 Phase 2 Ad26.ZEBOV/MVA-BN-Filo
26 Partnership for Research on Ebola VACcinations (PREVAC) Active, not recruiting NCT02876328 Phase 2
27 Open-label Phase 2 Study to Evaluate the Immunogenicity and Safety of a Prophylactic Vaccination of Health Care Providers by Administration of a Heterologous Vaccine Regimen Against Ebola in the Democratic Republic of the Congo Active, not recruiting NCT04186000 Phase 2
28 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Active, not recruiting NCT02344407 Phase 2
29 Phase IIa Pilot Study Evaluating the Efficacy of a Monoclonal Antibody and Vaccine-based Post-exposure Prophylaxis Strategy in High-risk Contact Cases of Ebola Virus Disease Infection Not yet recruiting NCT04822376 Phase 2 ansuvimab
30 An Open Label Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Children Previously Vaccinated With the Ad26.ZEBOV and MVA-BN-Filo Vaccine Regimen Not yet recruiting NCT04711356 Phase 2 Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection
31 Tolerance and Activity Assessment of High Doses of Favipiravir in Male Survivors With Ebola Virus in the Semen Terminated NCT02739477 Phase 2 Favipiravir
32 An Open-Label, Multicenter Study of the Safety and Tolerability of Brincidofovir (CMX001) for Post-Exposure Prophylaxis of Ebola Virus Disease Withdrawn NCT04268966 Phase 2 Brincidofovir
33 An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease Withdrawn NCT02271347 Phase 2 CMX001
34 A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of MVA-EBO Z Alone and a Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy UK Volunteers Unknown status NCT02451891 Phase 1
35 A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya. Unknown status NCT02296983 Phase 1
36 A Phase I Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6002 in Healthy Adult Volunteers Completed NCT01353027 Phase 1 Placebo;AVI-6002
37 A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Ebola Adenoviral Vector Vaccine, VRC-EBOADV018-00-VP, in Healthy Adults Completed NCT00374309 Phase 1 VRC-EBOADV018-00-VP
38 A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years. Completed NCT02485912 Phase 1
39 A Phase 1, Dose-escalation, Open Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV) in Healthy Adult Africans Aged Between 18-60 Years in China Completed NCT02401373 Phase 1
40 A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Monovalent Ebola Zaire Vaccine (rVSVN4CT1-EBOVGP1) Delivered by Intramuscular Injection in Healthy Adult Subjects Completed NCT02718469 Phase 1
41 A Phase IB Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Plasmid Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults in Kampala, Uganda Completed NCT00997607 Phase 1
42 A Phase I, Safety and Immunogenicity Trial of the Heterologous Prime-boost Regimen Combining the Monovalent Zaire Ebola Viral Vector Candidates ChAd3-EBO-Z and Ad26.ZEBOV in Healthy UK Adults Completed NCT02495246 Phase 1
43 Safety and Immunogenicity of a Booster Dose of the Recombinant Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults After Primary Immunization Completed NCT02533791 Phase 1
44 A Phase 1b, Dose-escalating Safety and Immunogenicity Trial of the Novel Monovalent Ebola Zaire Candidate Vaccine, cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen of cAD3-EBO Z Followed by MVA-BN® Filo in Malian Adults Aged 18-50 Years. Completed NCT02267109 Phase 1
45 A PHASE IB, DOUBLE-BLIND, CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF TWO DIFFERENT DOSAGE LEVELS OF EBOLA CHIMPANZEE ADENOVIRUS VECTOR VACCINE "VRC-EBOADC069-00-VP (cAd3-EBO)" AND THE HETEROLOGOUS PRIME-BOOST CANDIDATE VACCINE REGIMEN OF cAD3-EBO FOLLOWED BY MVA-VECTORED VACCINE IN HEALTHY ADULTS, 18-65 YEARS OF AGE, IN BAMAKO, MALI Completed NCT02368119 Phase 1
46 A Phase 1 Double-blind, Dose-escalation, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults in China Completed NCT02326194 Phase 1
47 Phase 1 Evaluation of a Live Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein Completed NCT02564575 Phase 1
48 An Open Label, Single Center, Dose Escalation Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Single Ascending Dose of the Ebola Virus Vaccine rVSVΔG-ZEBOV-GP (BPSC1001) Completed NCT02283099 Phase 1
49 Phase 1B, Open-Label, Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Investigational Ebola Vaccines, VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP and VRC-EBOMVA079-00-VP in Healthy Adults in Kampala Uganda Completed NCT02354404 Phase 1
50 VRC 204 A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiple Strain Ebola DNA Plasmid Vaccine, VRC-EBODNA012-00-VP, in Adult Volunteers Completed NCT00072605 Phase 1 VRC-EBODNA012-00-VP

Search NIH Clinical Center for Ebola Hemorrhagic Fever

Cochrane evidence based reviews: hemorrhagic fever, ebola

Genetic Tests for Ebola Hemorrhagic Fever

Genetic tests related to Ebola Hemorrhagic Fever:

# Genetic test Affiliating Genes
1 Ebola Hemorrhagic Fever 29

Anatomical Context for Ebola Hemorrhagic Fever

MalaCards organs/tissues related to Ebola Hemorrhagic Fever:

40
Eye, Lung, Skin, Monocytes, Whole Blood, Endothelial, Adrenal Gland

Publications for Ebola Hemorrhagic Fever

Articles related to Ebola Hemorrhagic Fever:

(show top 50) (show all 2378)
# Title Authors PMID Year
1
High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. 61
33719915 2021
2
Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases. 61
33596516 2021
3
Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease. 61
33789012 2021
4
Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study. 61
33065039 2021
5
Progress of public health policy regarding global infectious diseases over the past decade in Japan. 61
33472748 2021
6
Increased Likelihood of Detecting Ebola Virus RNA in Semen by Using Sample Pelleting. 61
33755000 2021
7
WHO guidance on ethics in outbreaks and the COVID-19 pandemic: a critical appraisal. 61
33789948 2021
8
Ebola virus outbreak preparedness plan for developing Nations: Lessons learnt from affected countries. 61
33610938 2021
9
Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein. 61
33691133 2021
10
Nurses at the frontline of public health emergency preparedness and response: lessons learned from the HIV/AIDS pandemic and emerging infectious disease outbreaks. 61
33743850 2021
11
[Ebola virus (Filoviridae: Ebolavirus: Zaire ebolavirus): fatal adaptation mutations]. 61
33683061 2021
12
Contextualizing Risk Perception and Trust in the Community-Based Response to Ebola Virus Disease in Liberia. 61
33809944 2021
13
Heterogeneity of contact patterns with Ebola virus disease cases. 61
33745916 2021
14
Mucosal Challenge Ferret Models of Ebola Virus Disease. 61
33806375 2021
15
Emerging paradigms of viral diseases and paramount role of natural resources as antiviral agents. 61
33234268 2021
16
Lessons from the Ebola epidemics and their applications for COVID-19 pandemic response in sub-Saharan Africa. 61
32654261 2021
17
The influence and enlightenment of five public health emergencies on public psychology since new century: A systematic review. 61
33722089 2021
18
Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. 61
33780452 2021
19
Transcriptomic Analysis Reveals Host miRNAs Correlated with Immune Gene Dysregulation during Fatal Disease Progression in the Ebola Virus Cynomolgus Macaque Disease Model. 61
33806942 2021
20
Strengthening the community health program in Liberia: Lessons learned from a health system approach to inform program design and better prepare for future shocks. 61
33763217 2021
21
Metagenomic Snapshots of Viral Components in Guinean Bats. 61
33803988 2021
22
The Impact of Water Sanitation and Hygiene (WASH) Improvements on Hand Hygiene at Two Liberian Hospitals during the Recovery Phase of an Ebola Epidemic. 61
33806086 2021
23
Persistence of Ebola virus in semen among Ebola virus disease survivors in Sierra Leone: A cohort study of frequency, duration, and risk factors. 61
33566817 2021
24
Development of a Well-Characterized Rhesus Macaque Model of Ebola Virus Disease for Support of Product Development. 61
33652589 2021
25
Understanding the long-term evolution and predictors of sequelae of Ebola virus disease survivors in Guinea: A 48-month prospective, longitudinal cohort study (PostEboGui). 61
33621316 2021
26
The year's new drugs and biologics 2020. 61
33656016 2021
27
Institutional policies and readiness in management of critical illness among patients with viral hemorrhagic fever. 61
33583468 2021
28
Ophthalmic and psychosocial sequelae in Ebola virus disease survivors: ongoing need for health systems strengthening across disciplines. 61
32772594 2021
29
Development of Pandemic Vaccines: ERVEBO Case Study. 61
33668698 2021
30
Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. 61
33536172 2021
31
Transcriptional Analysis of Lymphoid Tissues from Infected Nonhuman Primates Reveals the Basis for Attenuation and Immunogenicity of an Ebola Virus Encoding a Mutant VP35 Protein. 61
33408171 2021
32
A Glycoprotein Mutation That Emerged during the 2013-2016 Ebola Virus Epidemic Alters Proteolysis and Accelerates Membrane Fusion. 61
33593971 2021
33
Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic. 61
33608536 2021
34
Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. 61
33428961 2021
35
Screening of inhibitors as potential remedial against Ebolavirus infection: pharmacophore-based approach. 61
31928158 2021
36
Remote-Controlled and Pulse Pressure-Guided Fluid Treatment for Adult Patients with Viral Hemorrhagic Fevers. 61
33591934 2021
37
Psychological distress among adults from the urban and rural areas affected by the Ebola virus disease in the Democratic Republic of the Congo. 61
32537693 2021
38
Self-reported challenges to border screening of travelers for Ebola by district health workers in northern Ghana: An observational study. 61
33400709 2021
39
Superspreaders: A Lurking Danger in the Community. 61
33448254 2021
40
Neurologic Manifestations of the World Health Organization's List of Pandemic and Epidemic Diseases. 61
33692745 2021
41
Assessing anxiety, depression and insomnia symptoms among Ebola survivors in Africa: A meta-analysis. 61
33544772 2021
42
Ethics of emerging infectious disease outbreak responses: Using Ebola virus disease as a case study of limited resource allocation. 61
33529237 2021
43
Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes. 61
33350932 2021
44
Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon. 61
33776420 2021
45
Analysis of an Ebola virus disease survivor whose host and viral markers were predictive of death indicates the effectiveness of medical countermeasures and supportive care. 61
33430949 2021
46
Efficacy and Safety Outcomes of Cataract Surgery in Survivors of Ebola Virus Disease: 12-Month Results From the PREVAIL VII Study. 61
33520427 2021
47
Favipiravir in Therapy of Viral Infections. 61
33451007 2021
48
Chainchecker: An application to visualise and explore transmission chains for Ebola virus disease. 61
33606709 2021
49
Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop. 61
33436428 2021
50
An Ophthalmologist's Insight Into The Viral Pandemics. 61
33422421 2021

Variations for Ebola Hemorrhagic Fever

Expression for Ebola Hemorrhagic Fever

Search GEO for disease gene expression data for Ebola Hemorrhagic Fever.

Pathways for Ebola Hemorrhagic Fever

Pathways related to Ebola Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13 IRF3 IFNB1 IFNA1 DDX58 CXCL10 CCL4L1
2
Show member pathways
12.97 KPNA5 IRF3 IFNB1 IFNA1 DDX58 CXCL10
3
Show member pathways
12.75 IRF3 IFNB1 IFNA1 CD4 CCL4L1 CCL4
4 12.35 IRF3 IFNA1 DDX58 CXCL10 CD8A
5
Show member pathways
12.34 KPNA5 IRF3 IFNB1 IFNA1 DDX58 CXCL10
6
Show member pathways
12.26 IRF3 IFNB1 IFNA1 DDX58 CXCL10
7
Show member pathways
12.21 KPNA5 IRF3 IFNB1 IFNA1 DDX58
8 11.84 IRF3 IFNB1 CD8A CD4
9 11.7 DDX58 CCL4L1 CCL4
10
Show member pathways
11.67 IRF3 IFNB1 IFNA1 DDX58 CXCL10 CCL4L1
11 11.54 IFNB1 CD8A CD4
12
Show member pathways
11.31 CD8A CD4 CCL4L1 CCL4

GO Terms for Ebola Hemorrhagic Fever

Cellular components related to Ebola Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 IFNB1 IFNA1 GP2 FURIN F5 F3
2 extracellular region GO:0005576 9.32 NPC1 IFNB1 IFNA1 GP2 FURIN F5

Biological processes related to Ebola Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.89 GTPBP1 CXCL10 CD8A CD4 CCL4
2 viral process GO:0016032 9.85 NPC1 KPNA5 IRF3 FURIN DDX58 CD4
3 blood coagulation GO:0007596 9.71 IFNB1 IFNA1 F5 F3
4 neutrophil chemotaxis GO:0030593 9.65 CXCL10 CCL4L1 CCL4
5 defense response to virus GO:0051607 9.65 IRF3 IFNB1 IFNA1 DDX58 CXCL10
6 chemokine-mediated signaling pathway GO:0070098 9.63 CXCL10 CCL4L1 CCL4
7 response to virus GO:0009615 9.62 IFNB1 DDX58 CXCL10 CCL4
8 type I interferon signaling pathway GO:0060337 9.61 IRF3 IFNB1 IFNA1
9 positive regulation of calcium-mediated signaling GO:0050850 9.51 CD4 CCL4
10 cytokine-mediated signaling pathway GO:0019221 9.43 IFNB1 IFNA1 F3 CXCL10 CD4 CCL4
11 cellular response to exogenous dsRNA GO:0071360 9.33 IRF3 IFNB1 DDX58
12 response to exogenous dsRNA GO:0043330 8.92 IRF3 IFNB1 IFNA1 DDX58

Molecular functions related to Ebola Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IFNB1 IFNA1 CXCL10 CCL4
2 chemokine activity GO:0008009 8.8 CXCL10 CCL4L1 CCL4

Sources for Ebola Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....